The BD&L Summit for Life Sciences

Unlock the potential of a deal through optimized business development activities and transactional excellence to drive a company's competitive position in today's marketplace

San Francisco, CA, United States

The growing emergence of biotech companies and specialized knowledge base has lead to a shift in strategic focus for life science companies. Even though R&D spend is on the rise, companies still look to external targets as a means of supplementing pipelines and bolstering their product portfolios. The need to expand the reach of R&D programs has driven major new investments in co-development, licensing, acquisitions and strategic alliances, as companies look to gain access to new sources of innovation.

With so many factors affecting the potential value of a transaction, it is essential for life science organizations to effectively assess the risks associated with a deal, explore innovative models and deal structures for working with strategic partners, collaborate with cross-functional partners to realize business synergies, and develop processes for the efficient and optimal negotiation and closing of a transaction.

The BD&L Summit for Life Sciences will provide attendees with valuable insights and actionable strategies from cross-functional business development teams in successfully managing alliances, licensing agreements, and M&A deals. This event serves as an educational platform for industry experts responsible for R&D, search and evaluation, external innovation, legal/IP, portfolio management, alliance management, business development and licensing, and will feature leadership representation from biotechs, mid-sized and large pharmaceutical, medical device and diagnostics companies.

Who Should Attend:

This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas:
  • Business Development
  • Mergers and Acquisitions
  • Licensing
  • Strategic Alliance/Alliance Management
  • Intellectual Property and Patent Counsel
  • Search and Evaluation
  • Due Diligence
  • External Innovation
  • Transactions
  • Portfolio Management
  • Scientific Assessment
  • General Counsel/Corporate Counsel
  • Legal and Regulatory Compliance
  • Regulatory Affairs
  • Research and Development
  • Clinical Medicine
  • Clinical Operations
  • Lifecycle Management
This conference is also of interest to:
  • Investment Banks
  • Private Equity Firms
  • Venture Capitalists
  • Data Room Providers
  • Due Diligence Consultants
  • Law Firms
  • Clinical Affairs and CRO Partners
  • Regulatory Affairs and Compliance Partners


  • Brian Axe, Due Diligence Leader, ELANCO
  • Matthew Batters, J.D., Executive Director, Transactions, Alliance Management, Business Development and Corporate Counsel, ARVINAS
  • Lisa Beck, Vice President, Business Development and Alliance Management, BRII BIOSCIENCES
  • Zubin Bhagwagar, M.D., Ph.D., Global Program Lead, RALLYBIO
  • Janice Bourque, Managing Director, Life Sciences, HERCULES CAPITAL
  • Isaac J. Bright, Chief Executive Officer, RUBRYC THERAPEUTICS
  • Brian Bronk, Ph.D., Head of External Innovation, Rare Diseases, SANOFI
  • Sascha Bucher, Head of Global Transactions and Head Basel Office, ROIVANT SCIENCES
  • Kleem Chaudhary, Head BD&L MS, AD, OPN, Platforms, BIOGEN
  • Philip Datlow, Director and Senior Counsel, Intellectual Property, BOEHRINGER INGELHEIM
  • Behrad Derakhshan, Ph.D., Vice President, Head of Business Development, THERACON
  • Niels P. Emmerich, Vice President, Global Head Search and Evaluation, ABBVIE
  • John Fair, Chief Business Officer, DARE BIOSCIENCE
  • Teresa Faria, Senior Director, Alliance Management, External Scientific Affairs, DAIICHI SANKYO
  • Steven Gurney, Principal Associate and Patent Attorney, MARKS & CLERK
  • Joe Herold, Chief Legal Officer and Chief Compliance Officer, DRI CAPITAL
  • Timothy Herpin, Chief Business Officer, CARIBOU BIOSCIENCES
  • Ruby Holder, Vice President, Investments, ROIVANT SCIENCES
  • Rick Hoyt, Vice President, Business Development and Licensing, MALLINCKRODT
  • Will James, Partner and Solicitor, MARKS & CLERK
  • Chinmay Kanuga, Director, Scientific Assessments and Due Diligences, ALLERGAN
  • Adam Kundzewicz, Ph.D., Head of Strategic Market Access Initiatives, BOEHRINGER INGELHEIM
  • Tom Lynch, Chief Administrative Officer, General Counsel and Secretary, OREXIGEN
  • Bethany Mancilla, Chief Business Officer and Senior Vice President, CUE BIOPHARMA
  • Mike Myers, Senior Director, Lilly Research Labs - Due Diligence, ELI LILLY
  • Carolyn Ng, Principal, VERTEX VENTURES HC
  • George Ng, President, Business, SCILEX PHARMACEUTICALS
  • Tara Nickerson, Chief Business Officer, THIRD ROCK VENTURES
  • Mark E. Nuttall, Chief Business Officer, KYMERA THERAPEUTICS
  • William Pedranti, President, Operations, SCILEX PHARMACEUTICALS
  • Martin Picard, Ph.D., Vice President, Global Head Search, Evaluation and Due Diligence, MERCK KGAA
  • Joel Sangerman, Chief Commercial Officer, CLICK THERAPEUTICS
  • Marc Schwabish, Senior Vice President, Business Development and U.S. Operations, FUSION PHARMACEUTICALS
  • Peter Seufer-Wasserthal, Chief Business Officer, ORIGENIS
  • Felice Shieh, Senior Director, External Science and Innovation, PFIZER
  • Kristen B. Slaoui, Vice President, Head of Business Development, North America, Corporate Strategy and Development, GSK
  • Chris Slavinsky, Assistant General Counsel, PFIZER
  • Jackie Spencer, Managing Director, Life Sciences and Healthcare, SILICON VALLEY BANK
  • Peter Trybus, Senior Corporate Counsel, Healthcare Law, Managed Care Practice Group, GENENTECH
  • Michah Zajic, Vice President, Corporate Development, MEIRAGTX


Hyatt Fisherman's Wharf
555 North Point Street
San Francisco, CA 94133
Event details
Organizer : ExL Events
Venue : Hyatt Fisherman's Wharf, San Francisco, CA, United States
Event type : Conference
Reference : ASDE-19088